Netherlands Discussion Group

The Netherlands Area Biotech (NLab) Discussion Group is the first CASSS discussion group located outside the US and is intended to enable the local area community of industry, academic, and regulatory professionals to meet and share ideas and experiences, thereby working together to resolve scientific challenges in the field of biopharmaceutical development and regulation.

The NLab discussion group goals include:

  • Share learning across industry, academia, and health authorities in Europe in general, and in the Netherlands in particular.
  • Generate new scientific and technical insights and solutions for developing biopharmaceutical products in the future.
  • Contribute to the expansion of CASSS’ mission, vision, influence, and community in Europe.

Attend

Prioritizing Patient Involvement: The Key to Successful Drug Development | Leiden, Netherlands | 20 June 2024 16:30 - 18:30 CET

In our collective endeavor to develop innovative pharmaceuticals to fight diseases, we embark on a journey of discovery, innovation, and the meticulous generation of data. This data eventually converges into a comprehensive new drug application. However, beyond the stringent scientific evaluation and regulatory approval process lies the true litmus test: the patients' experience with the drug.

It is essential to consider whether the drug effectively addresses patients' needs, if it alleviates their most burdensome symptoms, if it's tolerable, if adherence to the treatment is feasible, and if the dosing schedule is practical. These are pivotal questions we should ask ourselves throughout the drug development journey.

Recognizing the invaluable insights patients provide, it is fundamental to involve them from the get-go. In our upcoming event, van Tomme will shed light on global trends in patient engagement and provide concrete examples demonstrating the integration of patient perspectives into the drug development process. To complement van Tomme’s industry perspective, Veltrop-Duits will share the Dutch regulator’s perspective, underscoring the significance of patient participation in clinical research.

Location:
Leiden University Medical Center (LUMC)
Albinusdreef 2, 2333 ZA Leiden, Netherlands

Registration closed 19 June 2024.

Abstract

In our collective endeavor to develop innovative pharmaceuticals to fight diseases, we embark on a journey of discovery, innovation, and the meticulous generation of data. This data eventually converges into a comprehensive new drug application. However, beyond the stringent scientific evaluation and regulatory approval process lies the true litmus test: the patients' experience with the drug.

It is essential to consider whether the drug effectively addresses patients' needs, if it alleviates their most burdensome symptoms, if it's tolerable, if adherence to the treatment is feasible, and if the dosing schedule is practical. These are pivotal questions we should ask ourselves throughout the drug development journey.

Recognizing the invaluable insights patients provide, it is fundamental to involve them from the get-go. In our upcoming event, van Tomme will shed light on global trends in patient engagement and provide concrete examples demonstrating the integration of patient perspectives into the drug development process. To complement van Tomme’s industry perspective, Veltrop-Duits will share the Dutch regulator’s perspective, underscoring the significance of patient participation in clinical research.

Featured Speakers

NLab Featured Presenters Sophie van Tomme, Sanofi B.V., Louise Veltrop-Duits, CCMO

Sophie van Tomme, Sanofi B.V.

In her current position at Sanofi, Sophie van Tomme's primary objective is to integrate the patient voice into the R&D programs, to facilitate patient-friendly clinical trial design, and to ultimately ensure that the products we bring to market genuinely improve patients' lives. Her professional background encompasses various roles within the pharmaceutical industry, particularly in drug product development and project management. Following Sanofi's acquisition of a small biotech company, she intentionally transitioned to a role within the patient-informed development team to allow her to be "closer to the patient”.

She studied pharmacy at the University of Ghent, followed by a PhD in advanced drug delivery at the University of Utrecht. She started her industry career as a formulation scientist in early pharmaceutical development at Solvay Pharmaceuticals (now Abbott). Subsequently, she had various roles in project management and drug product development at Nordic Pharma. In 2020 she joined Kiadis Pharma, a small biotech dedicated to Natural-Killer cells, where she was responsible for setting up a project-centric way of working.

Louise Veltrop-Duits, Central Committee on Research Involving Human Subjects (CCMO)

At the Central Committee on Research involving Human Subject (CCMO), Louise Veltrop-Duits is one of the project leaders of the Patient Participation programme. In this large programme, which consists of several themes, they want to give patients a (clearer) voice in both the design and conduct, but also in the ethical review of clinical research. After all, patients are experts by experience and it is a waste not to put that knowledge to good use. In various ways, they are trying to increase patient voice in clinical research. In addition to the Patient Participate programme, she works as an oversight officer and advisor to the board at the CCMO.

Veltrop-Duits was trained as a medical biologist at the VU in Amsterdam and then worked as a researcher and quality advisor at the LUMC in Leiden.

Promote Your Participation

 

Orange background with text 'Attendee Media Kit'
Orange background with text 'Presenter Media Kit'

Here are some ways you can share your message:

  1. Follow CASSS on Facebook, Twitter, and LinkedIn. Stay up-to-date on the latest Discussion Group announcements and opportunities. Links can be found in the right column or at the bottom of this page.
  2. Share your participation via your personal Facebook, Twitter, and LinkedIn accounts. Whether you are a recurring presenter or this is your first time attending, we are grateful to have you join us this year.
  3. Share the news with your colleagues who run your organization's official social media channels. We are proud to show our community your participation - let your community convey their support too.
  4. Join our CASSS LinkedIn Group to help create additional discussion before the Discussion Group and beyond about topics of interest with like-minded people. https://www.linkedin.com/groups/2361040/
  5. Personalize your email signature. Add an image or short message to your default email signature to let your colleagues know you will be attending the Discussion Group. 
  6. Remember to tag CASSS on all social media posts.

If you have any questions about this media kit, please reach out to Renee Olson.

Thank You for Joining Us

We appreciate your participation in the Netherlands Area Biotech (NLab) Discussion Group on 20 June 2024 in Leiden, Netherlands and hope you consider joining us next time. More information coming soon.

Image with text 'CASSS Discussion Groups'

Join the CASSS Network

Join the community discussion and network with other professionals from industry, academia, and regulatory agencies.

LinkedIn  LinkedIn Group 

Facebook  X  YouTube